The US Food and Drug Administration (FDA) and Boston-based wearable maker Whoop are having a bit of a back-and-forth.
The spat was revealed in an FDA warning letter sent to Whoop CEO Will Ahmed on July 14.
According to that letter, on two separate days, May 15 and May 27, Ahmed
Medical device
Free Trial
Register for free to keep reading.
To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.
- Unlimited access to industry insights
- Stay on top of key rules and regulatory changes with our Rules Navigator
- Ad-free experience with no distractions
- Regular podcasts from trusted external experts
- Fresh compliance and regulatory content every day
